Welcome subscribers,
In this week's newsletter, we examine how pharma leaders are happy to mix leases and ownership, balancing cost efficiency, flexibility, and strategic control amid market shifts. You will also find key updates on deals across the UK and Europe:
✅ Germany: iQ Spaces in Munich
🔒 Denmark: FUJIFILM Diosynth Biotechnologies expands
🔒 Switzerland: Corden Pharma invests over €500 million
🔒 UK: KKR closes in on Assura
(🔒 for paying members only)
Read below for full details.
— Stephen Ryan (connect with me on LinkedIn)
Pharmaceutical companies and real estate: the rent versus buy decision
Industry leaders are shifting from traditional property ownership to strategic lease-ownership balancing for financial efficiency and flexibility.
🎯 Would you like to reach over 300 investors, developers, brokers and service providers in the life sciences real estate industry? You can now advertise in our weekly newsletter and deliver your message to our readers. Contact me if you are interested.
Transactions
GERMANY BERLIN
MyoPax has become the first tenant at Bayer Co.Lab, leasing laboratory and office space for research into muscle regeneration using stem cell and gene editing technologies. Bayer Co.Lab also has locations in Cambridge (USA), Kobe and Shanghai.
IRELAND DUBLIN
A dental practice in a Victorian building at 58 Northumberland Road, comprising 292.2 sq m and generating €160,000 annually, is listed for sale at €2.45 million (£2.1 million) There are scheduled rent increases to €175,500 (£147,000) in August 2025 and €191,000 (£160,000) in 2030.
UK BRACKNELL
Frasers Property UK leased 10,000 sq ft of fitted office space at Maxis Business Park to an unnamed pharmaceutical company, marking the second-largest letting at the park in the past year. Bracknell is at the western edge of London.
